GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » FCF Margin %

Halberd (Halberd) FCF Margin % : -8,033.33% (As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Halberd's Free Cash Flow for the six months ended in Jul. 2023 was $-0.24 Mil. Halberd's Revenue for the six months ended in Jul. 2023 was $0.00 Mil. Therefore, Halberd's FCF Margin % for the quarter that ended in Jul. 2023 was -8,033.33%.

As of today, Halberd's current FCF Yield % is -103.43%.

The historical rank and industry rank for Halberd's FCF Margin % or its related term are showing as below:

HALB' s FCF Margin % Range Over the Past 10 Years
Min: -11550   Med: -8033.33   Max: -4414.29
Current: -8033.33


During the past 3 years, the highest FCF Margin % of Halberd was -4414.29%. The lowest was -11550.00%. And the median was -8033.33%.

HALB's FCF Margin % is ranked worse than
90.63% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs HALB: -8033.33


Halberd FCF Margin % Historical Data

The historical data trend for Halberd's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd FCF Margin % Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
FCF Margin %
-4,414.29 -11,550.00 -8,033.33

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
FCF Margin % -4,414.29 -11,550.00 -8,033.33

Competitive Comparison of Halberd's FCF Margin %

For the Biotechnology subindustry, Halberd's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halberd's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Halberd's FCF Margin % falls into.



Halberd FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Halberd's FCF Margin for the fiscal year that ended in Jul. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Jul. 2023 )/Revenue (A: Jul. 2023 )
=-0.241/0.003
=-8,033.33 %

Halberd's FCF Margin for the quarter that ended in Jul. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Jul. 2023 )/Revenue (Q: Jul. 2023 )
=-0.241/0.003
=-8,033.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Halberd FCF Margin % Related Terms

Thank you for viewing the detailed overview of Halberd's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Halberd (Halberd) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236